To the Editor.—
The proposition from the National Institutes of Health Consensus Development Conference1 that one of every ten American adults should be given drug therapy to lower blood cholesterol levels is staggering and warrants further comment. In their "An Approach to the Management of Hyperlipoproteinemia,"2 Hoeg et al also recommended drug treatment for persons in the top tenth percentile and referred to the Coronary Drug Project as supporting the use of niacin. Challenged that no prospective drug trial has yet shown lower coronary mortality in the treatment group3— including the Coronary Drug Project— these advocates cited a follow-up study by Canner that might suggest a late beneficial effect of niacin.4
Norenberg DD. The Management of Hyperlipoproteinemia. JAMA. 1986;256(8):1003. doi:10.1001/jama.1986.03380080049024
Customize your JAMA Network experience by selecting one or more topics from the list below.